Press "Enter" to skip to content

Posts published in “Issue 3: November 2020”

The Work Begins Now

I had quite the shock last week. After eight months of what I thought were MBA courses at NYU Stern, I discovered I’ve actually been attending online classes with Stern Lawn N’ Landscaping, the only place in Wausau, Wis., worth calling if your home needs more curb appeal. While the employees have surprisingly deep knowledge of forecasting models and the Cobb-Douglas function — I mean, how else would it have taken me this long to notice? — it is clear I’ve been made a fool.

That tuition better cover a whole lot of lawn care.

Luckily, I learned last Saturday that I was in good company, though I use the term “good” loosely.…

The Election, the Vaccine, and the Moolah

If you haven’t heard Joe Biden is president-elect of the United States of America, you should probably stop reading now. The market had priced in several predictions for the US elections of 2020. We all know the polls were not as accurate as projected but, as usual, the devil is in the details. The Senate and House election outcomes have caused the major moves in the market thus far, not so much the presidential election. And don’t worry, we will obviously get into the Covid vaccine’s effects on the market, too.

First and foremost, the Senate and House election surprises. What this means in market speak is the unwinding of the “blue wave” bet.…

Pfizer’s COVID vaccine demonstrates efficacy in clinical trials. Now what?

Last Monday, Pfizer announced preliminary findings from Phase III of clinical trials demonstrate that its SARS-CoV2 vaccine is effective in producing antibodies against COVID. Pfizer partnered with German biotech firm, BioNTech, to produce the vaccine. Pfizer is one of the two forerunners in Phase III of clinical trials to prove efficacy of an mRNA vaccine. The other being Moderna. mRNA vaccines are developed from re-engineered messenger RNA (mRNA), the molecules that relay genetic instructions from DNA to the cell’s protein-making machinery. The company’s technology sends synthetic mRNA into cells, which would hypothetically invoke an immune response that causes the body to develop antibodies against the virus.…

Moderna’s Race for a Covid Vaccine: A Fireside Chat with Lavina Talukdar, Head of Investor Relations

On November 4th, Stern Healthcare Association (SHA) hosted a fireside chat with Moderna’s Head of Investor Relations, Lavina Talukdar. Ms.Talukdar joined Moderna in April 2019 after 20 years as a biotech and healthcare investor. She is an expert in the niche market of investment procurement for mRNA development. Professor Viral Acharya moderated the discussion. Professor Acharya is the C.V. Starr Professor of Economics in the Department of Finance at Stern and an Academic Advisor to the Federal Reserve Banks of New York and Philadelphia. The week of the event, he published a paper on the economic value a SARS-CoV-2 vaccine would bring to society. …

From Major to MBA

By Darwin Castillo

My training and unique experiences in the military have led me to become a better physician, educator, and leader. Growing up, I never would have seen myself in the military since I envisioned a career in a quiet laboratory, researching treatments for rare diseases. Throughout college and years after, I worked as a research scientist at the University of California – San Francisco, The Salk Institute, and The University of Tokyo. Transitioning into clinical medicine became an obvious choice when the highlights of my work schedule were weekly visits to operating rooms, emergency departments, and clinical offices to obtain samples and data for my research projects.…

Mission News Theme by Compete Themes.